Essais liés9clinical trials
VilleBaltimorelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06383390

Ouvrir le site du centre

Essais cliniques associés

9
MoléculeIndication / populationPhaseNCTTitreStatut
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL Maladie coronarienne Phase 3 NCT05739383 A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. ACTIVE_NOT_RECRUITING
Survodutide Maladie rénale chronique Phase 3 NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) COMPLETED
Maridebart cafraglutide Insuffisance cardiaque Phase 3 NCT07037459 MARITIME-HF — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity RECRUITING
Low Dose PF-07328948 Insuffisance cardiaque Phase 2 NCT06991257 A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) RECRUITING
QCZ484 Hypertension Phase 2 NCT06857955 A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients ACTIVE_NOT_RECRUITING
Vicadrostat Insuffisance cardiaque Phase 3 NCT06424288 A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure RECRUITING
Vicadrostat Insuffisance cardiaque Phase 3 NCT06935370 A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart RECRUITING
Retatrutide Maladie rénale chronique Phase 3 NCT06383390 The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) ACTIVE_NOT_RECRUITING
Vicadrostat Hypertension Phase 3 NCT07064473 EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease RECRUITING